INmune Bio Inc (NASDAQ:INMB) does about 304.28K shares in volume on a normal day but saw 859495 shares change hands in the recent trading day. The company now has a market cap of 182.90M USD. Its current market price is $7.88, marking an increase of 3.01% compared to the previous close of $7.65. The 52 week high reached by this stock is $10.50 whilst the lowest price level in 52 weeks is $4.32. The script in recent trading has seen the stock touch a high of $22 and a low of $22.
The consensus objective for the share price is $23.67, suggesting that the stock has a potential upside of 66.71% over the period. The median price target is 64.18% away from the current levels at $22.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 28, 2025 when Rodman & Renshaw initiated the stock to “Buy” and issued a price target of $23. Raymond James initiated its price target at $18.
The current price level is 4.59%, 4.66%, and 17.75% away from its SMA20, SMA50, and SMA200 respectively, with the INMB price moving above the 50-day SMA on current market day. INmune Bio Inc (INMB) stock is up 8.39% over the week and 13.06% over the past month. Its price is 68.74% year-to-date and -11.96% over the past year.
Its 12-month price target is $22. To reach the target analysts have set, the stock logically needs to grow 66.71 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $22, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $22.
Outstanding shares total 22.93M with insiders holding 28.19% of the shares and institutional holders owning 25.67% of the company’s common stock. The company has a return on investment of -136.56% and return on equity of -139.01%. The beta has a value of 1.57. Price to book ratio is 6.09 and price to sales ratio is 3658.00.
